HemoCER: Registry on the Use of HaemoCER-Plus in the Treatment and Prevention of Post-resectional Bleeding
Study Details
Study Description
Brief Summary
Gastrointestinal bleeding is defined as clinical evidence of bleeding manifested by melena, hematochezia that required endoscopic hemostasis. GI bleeding associated to endoscopic procedure is defined as clinical evidence of bleeding and a drop in hemoglobin of ≥ 2g/dL on the day of the procedure (early bleeding) or up to 14 days after the procedure (delayed bleeding).GI bleeding is, nevertheless, a common complication of endoscopic procedures, such as endoscopic mucosal resection (EMR) and endoscopic sub mucosal dissection (ESD). For example, colorectal ESD, which is technically more difficult than gastric or esophageal ESD because of the anatomical features of the colon, present an increased risk of delayed bleeding. According to literature, early bleeding occurs on average in 5,3% of endoscopic resections of the whole digestive tract, with bleeding rates per location as follows: esophagus 9.4%, stomach 9.1%, duodenum 3.6%, colon 3.4%. Concerning delayed bleeding, it is assessed to complicate 3.1% of endoscopic resection procedures. The bleeding rate in the duodenum is usually the highest (6.3%), followed by colon at (3.6%), stomach (1.5%) and esophagus (0.9%). Age, lesion size and piecemeal resection are associated with an increased risk of bleeding. Usage of aspirin or NSAIDs seems to not increase risk of post-polypectomy bleeding, while clopidogrel and warfarin do and should be discontinued in the periprocedural period to prevent the occurrence of post-polypectomy bleeding. Direct oral anticoagulants (DOAC) administration shows similar post-procedural gastrointestinal bleeding risk to anti-vitamin K antagonists (VKA) administration in patients undergoing endoscopic procedures.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| HaemoCer-PLUS Patients who had receive HaemoCer-PLUS |
Device: HaemoCer-PLUS
HaemoCer-PLUS
|
Outcome Measures
Primary Outcome Measures
- Number and proportion of bleeding events in patients receiving HaemoCer-PLUS [6 months]
Number and proportion of bleeding events controlled by application of HaemoCer
Eligibility Criteria
Criteria
Inclusion Criteria:
-
patients who had authorized to use and process their personal details for the purpose of research;
-
patients able to express their consent;
-
age >18 years;
-
endoscopic procedures where HaemoCer-PLUS has been used for hemostasis or prevention of bleeding
Exclusion Criteria:
-
hemostatic therapies other than HaemoCer-PLUS
-
Known coagulopathy likely to affect risk of bleeding.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Humanitas-Mater Domini | Castellanza | Italy | 21053 |
Sponsors and Collaborators
- Istituto Clinico Humanitas Mater Domini
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 11